Your shopping cart is currently empty

Hu7691 is an orally active, selective, and potent Akt inhibitor that targets Akt1, Akt2, and Akt3, while also inhibiting neuroblastoma cell proliferation and inducing their differentiation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | 1-2 weeks | 1-2 weeks | |
| 5 mg | Inquiry | 1-2 weeks | 1-2 weeks |
| Description | Hu7691 is an orally active, selective, and potent Akt inhibitor that targets Akt1, Akt2, and Akt3, while also inhibiting neuroblastoma cell proliferation and inducing their differentiation. |
| Targets&IC50 | PKA:11 nM, Akt2:97.5 nM, RSK1:756 nM, Akt1:4.0 nM, Akt3:28 nM, ROCK1:354 nM, p70 S6K:229 nM, PKCη:629 nM |
| In vitro | Hu7691 exhibits anti-proliferative and neurogenic effects on various neuroblastoma cell lines. This includes neurite outgrowth, cell cycle arrest, and differentiation mRNA markers, further elucidating the differentiation-inducing effects of Hu7691[3]. |
| In vivo | For a repeated dose toxicity study of Hu7691 in male and female Sprague Dawley (SD) rats over 14 consecutive days, the results indicated the following dosages: male rats received daily doses of 12.5, 50, 100, and 150 mg/kg, while female rats received daily doses of 12.5, 25, 50, and 75 mg/kg. Toxicity assessment revealed potential target organs including the spleen, thymus, and gastrointestinal tract[2]. |
| Molecular Weight | 450.88 |
| Formula | C22H22ClF3N4O |
| Cas No. | 2360523-76-6 |
| Smiles | N(C(=O)C1=C(F)C=C(C=C1)C2=CC=NN2C)[C@H]3[C@@H](CCNC3)C4=CC(F)=C(F)C=C4.Cl |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (177.43 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 5 mg/mL (11.09 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.